Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 20MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 20MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose 5% provides calories and fluid for hydration; sodium chloride 0.2% replaces sodium and chloride ions to maintain electrolyte balance; potassium chloride 20 mEq replaces potassium to maintain intracellular ion concentrations and nerve/muscle function.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion at a rate of 100-125 mL/hour, providing 5 g dextrose, 0.2 g sodium chloride, and 20 mEq potassium chloride per liter. Typical adult dose is 1 L every 8-12 hours, adjusted for electrolyte needs and fluid status.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Dextrose: ~2 hours for glucose; Sodium and chloride: not applicable; Potassium: ~12 hours (terminal) in normokalemia, prolonged in renal impairment.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: Dextrose is metabolized to CO2 and water, not excreted unchanged. Sodium and chloride are excreted renally; potassium is excreted renally (90%) and fecally (10%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte